|
1
|
Chao MV: Neurotrophins and their
receptors: A convergence point for many signalling pathways. Nat
Rev Neurosci. 4:299–309. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang EJ and Reichardt LF: Neurotrophins:
Roles in neuronal development and function. Annu Rev Neurosci.
24:677–736. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Douma S, Van Laar T, Zevenhoven J,
Meuwissen R, Van Garderen E and Peeper DS: Suppression of anoikis
and induction of metastasis by the neurotrophic receptor TrkB.
Nature. 430:1034–1039. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kupferman ME, Jiffar T, El-Naggar A,
Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, et al:
TrkB induces EMT and has a key role in invasion of head and neck
squamous cell carcinoma. Oncogene. 29:2047–2059. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Desmet CJ and Peeper DS: The neurotrophic
receptor TrkB: A drug target in anti-cancer therapy? Cell Mol Life
Sci. 63:755–759. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yilmaz T, Jiffar T, de la Garza G, Lin H,
Milas Z, Takahashi Y, Hanna E, MacIntyre T, Brown JL, Myers JN, et
al: Theraputic targeting of Trk supresses tumor proliferation and
enhances cisplatin activity in HNSCC. Cancer Biol Ther. 10:644–653.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee J, Jiffar T and Kupferman ME: A novel
role for BDNF-TrkB in the regulation of chemotherapy resistance in
head and neck squamous cell carcinoma. PLoS One. 7:e302462012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu Y, Zhang S, Wang X, Yang Z and Ou G:
Overexpression of TrkB promotes the progression of colon cancer.
APMIS. 118:188–195. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blondy S, Christou N, David V, Verdier M,
Jauberteau MO, Mathonnet M and Perraud A: Neurotrophins and their
involvement in digestive cancers. Cell Death Dis. 10:1232019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abate-Shen C: Deregulated homeobox gene
expression in cancer: Cause or consequence? Nat Rev Cancer.
2:777–785. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Friedmann Y, Daniel CA, Strickland P and
Daniel CW: Hox genes in normal and neoplastic mouse mammary gland.
Cancer Res. 54:5981–5985. 1994.PubMed/NCBI
|
|
12
|
Bhatlekar S, Fields JZ and Boman BM: HOX
genes and their role in the development of human cancers. J Mol Med
(Berl). 92:811–823. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhatlekar S, Fields JZ and Boman BM: Role
of HOX genes in stem cell differentiation and cancer. Stem Cells
Int. 2018:35694932018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang SL, Chan TC, Chen TJ, Lee SW, Lin LC
and Win KT: HOXC6 overexpression is associated with Ki-67
expression and poor survival in NPC patients. J Cancer.
8:1647–1654. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramachandran S, Liu P, Young AN, Yin-Goen
Q, Lim SD, Laycock N, Amin MB, Carney JK, Marshall FF, Petros JA,
et al: Loss of HOXC6 expression induces apoptosis in prostate
cancer cells. Oncogene. 24:188–198. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang P, Kang W, Pan Y, Zhao X and Duan L:
Overexpression of HOXC6 promotes cell proliferation and migration
via MAPK signaling and predicts a poor prognosis in glioblastoma.
Cancer Manag Res. 11:8167–8179. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ji M, Feng Q, He G, Yang L, Tang W, Lao X,
Zhu D, Lin Q, Xu P, Wei Y, et al: Silencing homeobox C6 inhibits
colorectal cancer cell proliferation. Oncotarget. 7:29216–29227.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim KJ, Moon SM, Kim SA, Kang KW, Yoon JH
and Ahn SG: Transcriptional regulation of MDR-1 by HOXC6 in
multidrug-resistant cells. Oncogene. 32:3339–3349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reiss K and Saftig P: The ‘a disintegrin
and metalloprotease’ (ADAM) family of sheddases: Physiological and
cellular functions. Semin Cell Dev Biol. 20:126–137. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gavert N, Sheffer M, Raveh S, Spaderna S,
Shtutman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E, et
al: Expression of L1-CAM and ADAM10 in human colon cancer cells
induces metastasis. Cancer Res. 67:7703–7712. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park GB and Kim D: TLR4-mediated
galectin-1 production triggers epithelial-mesenchymal transition in
colon cancer cells through ADAM10- and ADAM17-associated lactate
production. Mol Cell Biochem. 425:191–202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ishikawa N, Daigo Y, Yasui W, Inai K,
Nishimura H, Tsuchiya E, Kohno N and Nakamura Y: ADAM8 as a novel
serological and histochemical marker for lung cancer. Clin Cancer
Res. 10:8363–8370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wildeboer D, Naus S, Amy Sang QX, Bartsch
JW and Pagenstecher A: Metalloproteinase disintegrins ADAM8 and
ADAM19 are highly regulated in human primary brain tumors and their
expression levels and activities are associated with invasiveness.
J Neuropathol Exp Neurol. 65:516–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Romagnoli M, Mineva ND, Polmear M, Conrad
C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg
Á, McDermott EW, et al: ADAM8 expression in invasive breast cancer
promotes tumor dissemination and metastasis. EMBO Mol Med.
6:278–294. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Conrad C, Götte M, Schlomann U, Roessler
M, Pagenstecher A, Anderson P, Preston J, Pruessmeyer J, Ludwig A,
Li R, et al: ADAM8 expression in breast cancer derived brain
metastases: Functional implications on MMP-9 expression and
transendothelial migration in breast cancer cells. Int J Cancer.
142:779–791. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang Z, Bai Y, Huo L, Chen H, Huang J, Li
J, Fan X, Yang Z, Wang L and Wang J: Expression of A disintegrin
and metalloprotease 8 is associated with cell growth and poor
survival in colorectal cancer. BMC Cancer. 14:5682014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meng L, Liu B, Ji R, Jiang X, Yan X and
Xin Y: Targeting the BDNF/TrkB pathway for the treatment of tumors.
Oncol Lett. 17:2031–2039. 2019.PubMed/NCBI
|
|
28
|
Schlomann U, Koller G, Conrad C, Ferdous
T, Golfi P, Garcia AM, Höfling S, Parsons M, Costa P, Soper R, et
al: ADAM8 as a drug target in pancreatic cancer. Nat Commun.
6:61752015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park GB, Jeong JY and Kim D: Modified
TLR-mediated downregulation of miR-125b-5p enhances CD248
(endosialin)-induced metastasis and drug resistance in colorectal
cancer cells. Mol Carcinog. 59:154–167. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gomez DR, Byers LA, Nilsson M, Diao L,
Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, et al:
Integrative proteomic and transcriptomic analysis provides evidence
for TrkB (NTRK2) as a therapeutic target in combination with
tyrosine kinase inhibitors for non-small cell lung cancer.
Oncotarget. 9:14268–14284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen SW, Zhang Q, Xu ZF, Wang HP, Shi Y,
Xu F, Zhang WJ, Wang P and Li Y: HOXC6 promotes gastric cancer cell
invasion by upregulating the expression of MMP9. Mol Med Rep.
14:3261–3268. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang DD, Xu Y, Tu YL, Tan XL, Zhu ZM, Han
MM, Dou CQ, Zeng JP, Tan JW, Du JD, et al: Comparison analysis in
synchronous and metachronous metastatic colorectal cancer based on
microarray expression profile. Hepatogastroenterology.
61:2215–2218. 2014.PubMed/NCBI
|
|
33
|
Contreras-Zárate MJ, Day NL, Ormond DR,
Borges VF, Tobet S, Gril B, Steeg PS and Cittelly DM: Estradiol
induces BDNF/TrkB signaling in triple-negative breast cancer to
promote brain metastases. Oncogene. 38:4685–4699. 2019. View Article : Google Scholar
|
|
34
|
Meldolesi J: Neurotrophin Trk receptors:
New targets for cancer therapy. Rev Physiol Biochem Pharmacol.
174:67–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Watanabe Y, Saito M, Saito K, Matsumoto Y,
Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, et
al: Upregulated HOXA9 expression is associated with lymph node
metastasis in colorectal cancer. Oncol Lett. 15:2756–2762.
2018.PubMed/NCBI
|
|
36
|
López-Otín C and Hunter T: The regulatory
crosstalk between kinases and proteases in cancer. Nat Rev Cancer.
10:278–292. 2010. View Article : Google Scholar
|
|
37
|
Mason SD and Joyce JA: Proteolytic
networks in cancer. Trends Cell Biol. 21:228–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fu L, Liu N, Han Y, Xie C, Li Q and Wang
E: ADAM10 regulates proliferation, invasion, and chemoresistance of
bladder cancer cells. Tumour Biol. 35:9263–9268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang XJ, Feng CW and Li M: ADAM17 mediates
hypoxia-induced drug resistance in hepatocellular carcinoma cells
through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem.
380:57–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Park GB, Chung YH and Kim D:
2-Deoxy-D-glucose suppresses the migration and reverses the drug
resistance of colon cancer cells through ADAM expression
regulation. Anticancer Drugs. 28:410–420. 2017. View Article : Google Scholar : PubMed/NCBI
|
